Search Within

Philip Schulman

Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Hematologic Malignancies, Division of (6)
  4. Lymphoma (4)
  5. Radiology, Department of (3)
  6. Biostatistics Service (2)

More Groups

People
  1. Andrew Zelenetz (4)
  2. Ariela Noy (4)
  3. Carol Portlock (4)
  4. Craig Moskowitz (4)
  5. David Straus (4)
  6. John Gerecitano (4)

More People

Years
  1. 2012 (1)
  2. 2011 (2)
  3. 2009 (1)
  4. 2008 (2)
  5. 2005 (1)
  6. 2004 (1)
Publications
  1. Blood (2)
  2. Journal of Clinical Oncology (2)
  3. Annals of Oncology (1)
  4. Clinical Cancer Research (1)
  5. Leukemia Research (1)
  6. Leukemia and Lymphoma (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. American Society of Hematology (2)
  3. American Association for Cancer Research (1)
  4. Elsevier Ltd (1)
  5. Oxford University Press (1)
  6. Taylor & Francis Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
    Journal Article

    Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
    Leukemia and Lymphoma (2012)

    Fulltext@MSK | Save
  • High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
    Journal Article

    Stone, R. M.; Moser, B.; Sanford, B.; Schulman, P.; Kolitz, J. E.; Allen, S.; Stock, W.; Galinsky, I.; Vij, R.; Marcucci, G.; more...
    Leukemia Research (2011)

    Fulltext@MSK | Save
  • Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C. H.; Noy, A.; Straus, D.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J. F.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D. J.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P): Two dosing schedules of a novel phase I regimen in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
    Journal Article

    Feldman, E. J.; Brandwein, J.; Stone, R.; Kalaycio, M.; Moore, J.; O'Connor, J.; Wedel, N.; Roboz, G. J.; Miller, C.; Chopra, R.; more...
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (Pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902
    Meeting Abstract

    Stone, R. M.; Moser, B.; Schulman, P.; Barrier, R. C.; Kolitz, J. E.; Allen, S. L.; Stock, W.; Galinsky, I. A.; Khoury, H.; Larson, R. A.
    Blood (2004)

    Fulltext@MSK | Save